You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 10,709,674


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,709,674 protect, and when does it expire?

Patent 10,709,674 protects EPIDIOLEX and is included in one NDA.

This patent has thirty patent family members in nineteen countries.

Summary for Patent: 10,709,674
Title:Use of cannabinoids in the treatment of epilepsy
Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s): Guy; Geoffrey (London, GB), Wright; Stephen (London, GB), Devinsky; Orrin (New York, NY)
Assignee: GW Research Limited (Cambridge, GB)
Application Number:16/678,961
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 10,709,674

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Jazz Pharms Res EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME ⤷  Try a Trial
Jazz Pharms Res EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,709,674

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom1418171.3Oct 14, 2014

International Family Members for US Patent 10,709,674

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015332212 ⤷  Try a Trial
Australia 2021204353 ⤷  Try a Trial
Australia 2023258400 ⤷  Try a Trial
Brazil 112017007777 ⤷  Try a Trial
Canada 2963208 ⤷  Try a Trial
Cyprus 1123229 ⤷  Try a Trial
Denmark 3206716 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.